178 related articles for article (PubMed ID: 7912567)
21. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.
Isola J; Visakorpi T; Holli K; Kallioniemi OP
J Natl Cancer Inst; 1992 Jul; 84(14):1109-14. PubMed ID: 1352359
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer.
Toi M; Osaki A; Yamada H; Toge T
Eur J Cancer; 1991; 27(8):977-80. PubMed ID: 1832907
[TBL] [Abstract][Full Text] [Related]
23. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical study on the expression of c-erbB-2 oncoprotein in breast cancer.
Horiguchi J; Iino Y; Takei H; Yokoe T; Ishida T; Morishita Y
Oncology; 1994; 51(1):47-51. PubMed ID: 7903441
[TBL] [Abstract][Full Text] [Related]
25. Determination of epidermal growth factor receptor provides additional prognostic information to measuring tumor angiogenesis in breast carcinoma patients.
Weidner N; Gasparini G
Breast Cancer Res Treat; 1994 Jan; 29(1):97-107. PubMed ID: 7517222
[TBL] [Abstract][Full Text] [Related]
26. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study.
Klijn JG; Look MP; Portengen H; Alexieva-Figusch J; van Putten WL; Foekens JA
Breast Cancer Res Treat; 1994 Jan; 29(1):73-83. PubMed ID: 8018964
[TBL] [Abstract][Full Text] [Related]
28. EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Eur J Surg Oncol; 2002 Jun; 28(4):383-7. PubMed ID: 12099646
[TBL] [Abstract][Full Text] [Related]
29. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.
Sainsbury JR; Farndon JR; Needham GK; Malcolm AJ; Harris AL
Lancet; 1987 Jun; 1(8547):1398-402. PubMed ID: 2884496
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor and other oncogenes as prognostic markers.
Harris AL; Nicholson S; Sainsbury R; Wright C; Farndon J
J Natl Cancer Inst Monogr; 1992; (11):181-7. PubMed ID: 1627426
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status.
Torregrosa D; Bolufer P; Lluch A; López JA; Barragán E; Ruiz A; Guillem V; Munárriz B; García Conde J
Clin Chim Acta; 1997 Jun; 262(1-2):99-119. PubMed ID: 9204213
[TBL] [Abstract][Full Text] [Related]
32. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
33. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
34. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
Isola J; Weitz S; Visakorpi T; Holli K; Shea R; Khabbaz N; Kallioniemi OP
J Clin Oncol; 1993 Jan; 11(1):36-43. PubMed ID: 8093367
[TBL] [Abstract][Full Text] [Related]
35. Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer.
van Agthoven T; Timmermans M; Dorssers LC; Henzen-Logmans SC
Int J Cancer; 1995 Dec; 63(6):790-3. PubMed ID: 8847135
[TBL] [Abstract][Full Text] [Related]
36. Concurrent abnormal expression of ERBB-2, EGFR, and p53 genes and clinical disease progression of breast carcinoma.
Visscher DW; Castellani R; Wykes SM; Sarkar FH; Hussain ME
Breast Cancer Res Treat; 1993 Dec; 28(3):261-6. PubMed ID: 7912562
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the immunohistochemical expression of EGFR, c-erbB2 and p53 protein between primary and recurrent breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Breast Cancer; 2002; 9(2):111-7. PubMed ID: 12016390
[TBL] [Abstract][Full Text] [Related]
38. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins.
Zhang GJ; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S
Jpn J Clin Oncol; 1997 Dec; 27(6):371-7. PubMed ID: 9437997
[TBL] [Abstract][Full Text] [Related]
39. neu oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissues.
Tsutsumi Y; Naber SP; DeLellis RA; Wolfe HJ; Marks PJ; McKenzie SJ; Yin S
Hum Pathol; 1990 Jul; 21(7):750-8. PubMed ID: 1972932
[TBL] [Abstract][Full Text] [Related]
40. Receptor status, proliferating activity, and c-erbB2 oncoprotein. An immunocytochemical evaluation in breast cancer.
Campani D; Sarnelli R; Fontanini G; Martini L; Cecchetti D; De Luca F; Squartini F
Ann N Y Acad Sci; 1993 Nov; 698():167-73. PubMed ID: 7904137
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
